C4 Therapeutics Inc. stocks have been trading up by 8.62 percent after promising cancer drug development news boosted investor optimism.
Click Here for a Millionaire's POV on Trading CCCC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Updated Phase 1 data for cemsidomide plus dexamethasone in relapsed/refractory multiple myeloma showed a 53% overall response rate at the recommended Phase 2 dose.
- Responses to cemsidomide in this tough patient group were described as durable and deepening, with a generally manageable safety profile.
- C4 Therapeutics plans continued clinical development and combination studies for cemsidomide, with data slated for presentation at EHA 2026.
Live Update At 14:02:49 EDT: On Tuesday, June 30, 2026 C4 Therapeutics Inc. stock [NASDAQ: CCCC] is trending up by 8.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CCCC, the ticker for C4 Therapeutics, trades like a classic high-risk biotech: volatile chart, thin revenue, heavy cash burn, and big reliance on clinical headlines. Over the last few weeks, CCCC has pushed from the mid‑$3s to the mid‑$4s, with the latest session closing near $4.73 after touching $5.17 intraday. That is a strong momentum push, and traders are clearly keying off the positive cemsidomide data.
On the fundamentals side, C4 Therapeutics posted about $6.2M in quarterly revenue, but it is still a development‑stage story. The company lost roughly $25M for the quarter and burned about $30M in operating cash. That is typical for a small‑cap biotech chasing a big cancer indication, but it means the balance sheet matters. CCCC reported about $235.7M in cash and short‑term investments and a current ratio near 9, which gives it a runway but not forever.
More Breaking News
- FRSH Stock Grinds Higher As Freshworks Tightens Fundamentals
- Rocket Lab Stock Climbs As Wall Street Backs Space Launch Leader
- Rocket Lab Stock Rebounds As Analysts Back Space Launch Boom
- Red Cat Holdings RCAT Stock Rallies On Hellcat Drone Launch
Margins are deeply negative, returns on equity and assets are sharply in the red, and free cash flow is about -$30M. For traders, that says one thing: C4 Therapeutics lives and dies on trial data and capital access, not near‑term earnings.
Why Traders Are Watching CCCC Now
CCCC landed squarely on momentum screens after C4 Therapeutics released updated Phase 1 data for cemsidomide, its oral IKZF1/3 degrader, in heavily pretreated relapsed/refractory multiple myeloma. In this kind of end‑of‑the‑line patient group, any solid response rate grabs attention. Here, C4 Therapeutics is talking about a 53% overall response rate at the recommended Phase 2 dose and maximum tolerated dose when cemsidomide is combined with dexamethasone.
For traders, that 53% number is the headline. It signals real anti‑tumor activity in a population that has already burned through other options. The company also highlighted that responses were durable and tended to deepen over time, and that the safety profile remained “generally manageable.” In biotech trading, that combo — efficacy plus tolerable safety — is exactly what keeps a program alive and pushes it toward Phase 2.
CCCC is leaning into that momentum. Management says these Phase 1 data support continued development and planned combination studies for cemsidomide, with a formal presentation coming at EHA 2026. That EHA slot matters, because every big conference presentation is another potential catalyst on the calendar for C4 Therapeutics and CCCC traders.
You can already see the tape reacting. On the most recent day, CCCC gapped up around $4.35 and made a controlled, intraday trend higher into the $5 area before settling back under that level. Pullbacks held higher lows through the session, a classic sign of dip buyers stepping in. For short‑term traders, that behavior screams “news‑driven trend,” not random noise.
Conclusion
CCCC sits in that classic small‑cap biotech sweet spot where one data set can reshape how the market values the whole pipeline. With cemsidomide delivering a 53% overall response rate, durable and deepening responses, and a manageable safety profile in a very tough multiple myeloma cohort, C4 Therapeutics just took a meaningful step in proving this drug has real potential. The planned Phase 2 and combination studies, plus the EHA 2026 presentation, give CCCC a clear roadmap of future catalysts that active traders will track closely.
At the same time, the numbers remind everyone what game they are playing. C4 Therapeutics has negative earnings, negative free cash flow, and relies on its roughly $235.7M cash and short‑term investments to fund R&D. That is fine for a development‑stage biotech, but it keeps dilution risk on the table and forces traders to respect the downside if the story stumbles.
For traders in this market, CCCC is not about dividends or steady cash flows. It is about volatility, catalysts, and strict discipline. As Tim Sykes likes to say, “Hot sector + news catalyst + volume is my favorite pattern, but it only works if you cut losses quickly.” Active market participants who trade names like CCCC also need to focus on process and review, because, as Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. C4 Therapeutics just delivered the catalyst and the volume; it is on traders to manage the risk around CCCC’s next moves. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.